Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Adenocarcinoma of Lung 2Unspecified Childhood Solid Tumor, Protocol Specific 1Ovarian Neoplasms 1Limited Stage Small Cell Lung Cancer 1Carcinoma, Ovarian Epithelial 1Alveolar Childhood Rhabdomyosarcoma 1

Interventions

Carboplatin 28Paclitaxel 21Cisplatin 9Topotecan 8Docetaxel 7Taxes 6Oxaliplatin 5Gemcitabine 5Chemotherapy, Adjuvant 5Bevacizumab 5aldesleukin 4Interleukin-12 Subunit p35 4Erlotinib Hydrochloride 4Drug Therapy 4Interleukin-12 3Immunohistochemistry 3Imatinib Mesylate 3Gene Expression Profiling 3Flow Cytometry 3Filgrastim 3Cyclophosphamide 3Amplified Fragment Length Polymorphism Analysis 3trioctyl phosphine oxide 2temsirolimus 2sargramostim 2oregovomab 2ixabepilone 2irofulven 2cediranib 2carboxyamido-triazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Ovarian Epithelial × Tirapazamine × Clear all
NCT00020696 2012-01-10

Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡